Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.298 -0.032 (-2.38%)

Streaming Delayed Price Updated: 11:07 AM EDT, Jul 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MediciNova, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

February 20, 2023

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

February 08, 2023

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

January 30, 2023

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates ↗

September 14, 2022

Via Benzinga

MediciNova Posts Promising Data From COVID-19 Treatment Candidate ↗

June 08, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 25, 2023

Via Benzinga

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

January 12, 2023

Preliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and Therapeutics

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

January 10, 2023

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

January 09, 2023

From MediciNova, Inc.

Via GlobeNewswire

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

January 05, 2023

MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteers

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

December 06, 2022

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse

December 05, 2022

From MediciNova, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 14, 2022

Via Benzinga

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

July 27, 2022

From MediciNova, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Wednesday ↗

September 07, 2022

On Wednesday, 297 companies achieved new lows for the year.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary ↗

July 26, 2022

Via Benzinga

MediciNova Commences Mid-Stage Non-alcoholic Fatty Liver Disease Study ↗

July 26, 2022

MediciNova (NASDAQ: MNOV) initiated a Phase 2 clinical trial to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus...

Via Benzinga

MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

July 26, 2022

From MediciNova, Inc.

Via GlobeNewswire

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗

June 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

83 Biggest Movers From Yesterday ↗

June 09, 2022

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...

Via Benzinga

50 Stocks Moving In Wednesday's Mid-Day Session ↗

June 08, 2022

Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback.

Via Benzinga

The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗

June 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking ↗

April 08, 2022

MediciNova Inc (NASDAQ: MNOV) announced that

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

February 01, 2022

Rise and shine, trader! We're starting off another day of investing with a breakdown of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 31, 2022

Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1...

Via Benzinga

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data ↗

January 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 13, 2021

Gainers Arena Pharmaceuticals (NASDAQ:ARNA) stock moved upwards by 91.22% to $95.5 during Monday's pre-market session. The company's market cap stands at $5.8...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 13, 2021

Welcome back, investor! With our return from the weekend comes a dive into the biggest pre-market stock movers for Monday!

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 26, 2021

Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 68.43% to $17.18 during Friday's pre-market session. The market value of their outstanding shares is at $119.6...

Via Benzinga

68 Biggest Movers From Wednesday ↗

November 26, 2021

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (...

Via Benzinga

Topics Initial Public Offering

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

MediciNova, Inc. - Common Stock (NQ:MNOV)

All News about MediciNova, Inc. - Common Stock